[Assessment of cell proliferation based on group analysis of Ki-67 index in serous ovarian cancers].
OBJECTIVE
Ovarian neoplasms are very important problems in medicine, because they account for 23% of all female genital neoplasms, and they are the cause of 47% deaths among women suffering from cancers of the female reproductive organs. Growth of the neoplasms depends on the speed of cells' reproduction. Monoclonal antibody Ki-67 detects specific antigen--nonhistonic protein of cellular nucleus, which is characteristic for dividing cells. It gives the possibility of using Ki-67 to establish proliferating index, especially in intensely proliferating neoplasm tissues.


OBJECTIVE
The aim of the study was the evaluation of clinical parameters compared with histological and laboratory findings in serous carcinomas. The research analysed the level of proliferating index Ki-67 in patients with ovarian cancers and in control group.


METHODS
The material used consisted of 41 cases of serous ovarian cancer. For clinical examinations we chose only patients who underwent primary surgical operation. The control group for Ki-67 levels were 15 patients with benign serous ovarian adenomas.


METHODS
For showing Ki-67 reacting antigen in paraffin samples of ovarian cancer we used DAKO Serum (Rabbit Anti Human Ki-67 Antigen N 1574 LSAB). Tissue proliferation activity called proliferation index--IP Ki-67 was measured as a proportion of numbers of cells reacting with antigen to the total number of cells in the sample.


RESULTS
Mean level of IP Ki-67 in examined group was 29.01%, compared to 5.84% in the control group and that was statistically significantly higher (p<0.05).


CONCLUSIONS
The analysis of cells' proliferative activity differentiates benign adenomas from ovarian serous carcinomas. But I didn't find this kind of correlation among analysed clinical and laboratory parameters and the level of Ki-67 index in ovarian serous cancers.
Blok
Radosław
R
Klinika Ginekologii i Połoznictwa AM we Wrocławiu, Wrocław.
Blok
Krystian
K
Gryboś
Marian
M
Klimkiewicz
Dominika
D
Jeleń-Krzeszewska
Joanna
J
Latkowski
Krzysztof
K
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen / Q000032:analysis; D016022:Case-Control Studies; D049109:Cell Proliferation; D018284:Cystadenocarcinoma, Serous / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; D019394:Ki-67 Antigen